Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E

被引:112
作者
Andrieu, C. [1 ,2 ]
Taieb, D. [1 ,2 ]
Baylot, V. [1 ,2 ]
Ettinger, S. [3 ]
Soubeyran, P. [1 ,2 ]
De-Thonel, A. [4 ]
Nelson, C. [3 ]
Garrido, C. [4 ]
So, A. [3 ]
Fazli, L. [3 ]
Bladou, F. [5 ]
Gleave, M. [3 ]
Iovanna, J. L. [1 ,2 ]
Rocchi, P. [1 ,2 ]
机构
[1] INSERM, Stress Cellulaire U624, F-13009 Marseille, France
[2] Aix Marseille Univ, Marseille, France
[3] Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC, Canada
[4] INSERM, U866, Fac Med, Dijon, France
[5] Hop St Marguerite, Serv Urol, Marseille, France
关键词
prostate cancer; androgen independence; heat shock protein 27; eukaryotic translational initiation factor; ubiquitination; INITIATION-FACTOR; 4E; INDEPENDENT PROGRESSION; PROTEASOMAL DEGRADATION; 4E-BINDING PROTEIN-1; LNCAP TUMORS; CYCLIN D1; TRANSLATION; GROWTH; HEAT-SHOCK-PROTEIN-27; APOPTOSIS;
D O I
10.1038/onc.2009.479
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
One strategy to improve therapies in advanced prostate cancer (PC) involves targeting genes that are activated by androgen withdrawal to delay the emergence of the androgen-independent (AI) phenotype. Heat shock protein 27 (Hsp27) expression becomes highly upregulated in PC cells after androgen withdrawal or chemotherapy, in which it functions as a cytoprotective chaperone to confer broadspectrum treatment resistance. The purpose of this study is to elucidate anti-apoptotic pathways regulated by Hsp27 that are activated during PC progression. Using two-hybrid experiment, we found that Hsp27 was having a major role in the protein translational initiation process. Furthermore, using complementary DNA (cDNA) microarray analysis, 4E binding protein 1 was identified as being proportionately and highly regulated by Hsp27. These data led us to analyze the protein synthesis initiation pathway, which is a prerequisite for cell growth and proliferation. Using northern and western blot analysis, we found that Hsp27 downregulation decreased eukaryotic translation initiation factor 4E (eIF4E) expression at the protein, but not mRNA, level. The cytoprotection afforded by Hsp27 overexpression was attenuated by eIF4E knockdown using specific eIF4E short interfering RNA (siRNA). Co-immunoprecipitation and co-immunofluorescence confirmed that Hsp27 colocalizes and interacts directly with eIF4E. Hsp27-eIF4E interaction decreases eIF4E ubiquitination and proteasomal degradation. By chaperoning eIF4E, Hsp27 seems to protect the protein synthesis initiation process to enhance cell survival during cell stress induced by castration or chemotherapy. Forced overexpression of eIF4E induces resistance to androgen-withdrawal and paclitaxel treatment in the prostate LNCaP cells in vitro. These findings identify Hsp27 as a modulator of eIF4E and establish a potential mechanism for the eIF4E-regulated apoptosis after androgen ablation and chemotherapy. Targeting Hsp27-eIF4E interaction may serve as a therapeutic target in advanced PC. Oncogene (2010) 29, 1883-1896; doi:10.1038/onc.2009.479; published online 18 January 2010
引用
收藏
页码:1883 / 1896
页数:14
相关论文
共 48 条
  • [1] 4E-Binding protein 1:: A key molecular "Funnel factor" in human cancer with clinical implications
    Armengol, Gemma
    Rojo, Federico
    Castellvi, Josep
    Iglesias, Carmela
    Cuatrecasas, Miriam
    Pons, Berta
    Baselga, Jose
    Ramon y Cajal, Santiago
    [J]. CANCER RESEARCH, 2007, 67 (16) : 7551 - 7555
  • [2] Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase
    Arora, S
    Yang, JM
    Hait, WN
    [J]. CANCER RESEARCH, 2005, 65 (09) : 3806 - 3810
  • [3] When translation meets transformation: the mTOR story
    Averous, J.
    Proud, C. G.
    [J]. ONCOGENE, 2006, 25 (48) : 6423 - 6435
  • [4] Hormone therapy failure in human prostate cancer:: Analysis by complementary DNA and issue microarrays
    Bubendorf, L
    Kolmer, M
    Kononen, J
    Koivisto, P
    Mousses, S
    Chen, YD
    Mahlamäki, E
    Schraml, P
    Moch, H
    Willi, N
    Elkahloun, AG
    Pretlow, TG
    Gasser, TC
    Mihatsch, MJ
    Sauter, G
    Kallioniemi, OP
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (20) : 1758 - 1764
  • [5] Cornford PA, 2000, CANCER RES, V60, P7099
  • [6] Frankfurt OS, 1997, CLIN CANCER RES, V3, P465
  • [7] Treatment options in hormone-refractory metastatic prostate carcinoma
    Fusi, A
    Procopio, G
    Della Torre, S
    Ricotta, R
    Bianchini, G
    Salvioni, R
    Ferrari, L
    Martinetti, A
    Savelli, G
    Villa, S
    Bajetta, E
    [J]. TUMORI JOURNAL, 2004, 90 (06): : 535 - 546
  • [8] Gallagher Eva, 2006, Clin J Oncol Nurs, V10, P233, DOI 10.1188/06.CJON.233-240
  • [9] Heat shock proteins 27 and 70
    Garrido, Carmen
    Brunet, Mathilde
    Didelot, Celine
    Zermati, Yael
    Schmitt, Elise
    Kroemer, Guido
    [J]. CELL CYCLE, 2006, 5 (22) : 2592 - 2601
  • [10] HSP27 and HSP70 Potentially Oncogenic Apoptosis Inhibitors
    Garrido, Carmen
    Schmitt, Elise
    Cande, Celine
    Vahsen, Nicola
    Parcellier, Arnaud
    Kroemer, Guido
    [J]. CELL CYCLE, 2003, 2 (06) : 579 - 584